List view / Grid view
14 January 2015 | By GlobalData
The global Rheumatoid Arthritis (RA) treatment market value will witness steady growth, from $15.6 billion in 2013 to $19.3 billion in 2023, at a Compound Annual Growth Rate (CAGR) of 2.1%, according to research and consulting firm GlobalData...
14 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Eli Lilly and Company announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib (LY2157299)...
13 January 2015 | By kdm communications
Dolomite’s droplet generation system is helping AbVitro to identify potential therapeutic targets using its AbPair™ technology...
13 January 2015 | By Frost and Sullivan
Oncology, autoimmune and infectious diseases/vaccines are hot areas for novel therapeutics and in vitro diagnostics in 2015...
13 January 2015 | By eyeforpharma
Richard Bergström, Director General, EFPIA argued passionately in favour of the homogenisation of European HTA bodies and regulation, during a recent interview with Paul Simms, Chairman, eyeforpharma...
13 January 2015 | By Porter Novelli Limited
Roche welcomes the announcement from NHS England that patients can continue to access our breast cancer medicines Perjeta, Kadcyla and Avastin via the Cancer Drugs Fund (CDF), but is extremely disappointed that patients with advanced bowel and ovarian cancer will now be denied Avastin on the NHS, following their review…
12 January 2015 | By Bristol-Myers Squibb Company
Seattle Genetics, Inc. and Bristol-Myers Squibb Company announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials...
12 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that an open-label, randomized Phase 3 study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer (NSCLC) was stopped early because an assessment conducted by the independent Data Monitoring Committee...
9 January 2015 | By Daiichi Sankyo
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism...
8 January 2015 | By DWP Public Relations
Changing demographics, ever-evolving regulatory schemes, political pressure to cut costs and social pressure to improve care has led to strong growth in consulting to the global healthcare sector...
8 January 2015 | By Andrew Lloyd & Associates
Ozenoxacin, a novel bactericidal non-fluorinated quinolone, will complete a second phase III clinical trial in adult and paediatric patients with impetigo in the first quarter of 2015...
8 January 2015 | By Oxford Global Conferences
Oxford Global Conferences were proud to present the Drug Discovery USA Congress this October in Boston, USA...
7 January 2015 | By GlobalData
The celiac disease treatment market value will expand more than tenfold from an estimated $49.6 million in 2013 to $551.1 million by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 27.24%, according to research and consulting firm GlobalData...
7 January 2015 | By Mundipharma
Mundipharma announced that Targin® (Targinact®, Targiniq®), a fixed combination of prolonged-release oxycodone/naloxone, has received a positive European Commission decision for a new indication, as a second line symptomatic treatment for patients with severe to very severe idiopathic restless legs syndrome (RLS), after failure of dopaminergic therapy...
7 January 2015 | By Photocure
Cevira advances towards Phase 3 for treatment in patients with cervical high grade lesions (HSIL)...
